Treatment of skeletal muscle FAPs with CCN1/CYR61 leads to differentiation into adipocytes, which is linked to sarcopenic obesity in the CKD patients mentioned before [63]. The gene discussed is CCN1; the disease is obesity due to melanocortin 4 receptor deficiency.